Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lucia Lisi, Pedro Miguel Lacal, Maria Martire, Pierluigi Navarra, Grazia Graziani
Topics & Concepts
IpilimumabNivolumabCTLA-4ImmunotherapyTumor microenvironmentMedicineImmune checkpointCancer researchMonoclonal antibodyTremelimumabImmune systemCancer immunotherapyMelanomaCytotoxic T cellImmunologyAntigenT cellCancerBlockadeAntibodyInternal medicineBiologyReceptorIn vitroBiochemistryCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses